Hjem › Crohns sykdom › New York › New York City
Kliniske studier for Crohns sykdom i New York City, NY
35 studier for Crohns sykdom søker deltakere på steder i og rundt New York City (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
RekruttererFase 2
- New York Gastroenterology Associates - Upper East Side /ID# 281767, New York
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RekruttererFase 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
RekruttererFase 3
- New York Gastroenterology Associates ( Site 0253), New York
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
RekruttererFase 3
- NYU Langone Health - Inflammatory Bowel Disease Center (IBD) ( Site 5078), New York
- Weill Cornell Medical College, New-York Presbyterian Hospital ( Site 5079), New York
- New York Gastroenterology Associates ( Site 5013), New York
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
RekruttererFase 4
- New York Gastroenterology Associates, New York
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
RekruttererFase 2
- Northwell Health-Lenox Hill Hospital /ID# 265527, New York
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
RekruttererFase 3
- Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center, New York
- Icahn School of Medicine at Mount Sinai, New York
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
RekruttererFase 2
- Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH), New York
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
RekruttererFase 3
- New York Gastroenterology Associates, New York
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
RekruttererFase 2/3
- Inflammatory Bowel Disease Center at NYU Langone, New York
- Weill Cornell Medical College, New York
- Lenox Hill Hospital, New York
- og 1 flere
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
RekruttererFase 3
- New York Gastroenterology Associates, New York
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RekruttererFase 3
- Manhattan Clinical Research, LLC-Site Number: 8400069, New York
- NYU Langone Health-Site Number: 8400091, New York
- Columbia University Medical Center-Site Number: 8400138, New York
- og 2 flere
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RekruttererFase 3
- NYU Langone Health-Site Number: 8400091, New York
- Weill Cornell Medicine - NewYork-Presbyterian Hospital-Site Number: 8400040, New York
- New York Gastroenterology Associates-Site Number: 8400009, New York
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
RekruttererFase 3
- Icahn School of Medicine at Mount Sinai /ID# 254880, New York
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
RekruttererFase 3
- Icahn School of Medicine at Mount Sinai, New York
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
RekruttererFase 4
- NYU Langone Health, New York
Standardized Microbiota Transplant Therapy in Crohn's Disease
RekruttererFase 2
- NYU Langone Health, New York
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
RekruttererFase 3
- New York Gastroenterology Associates, New York
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
RekruttererFase 3
- Weill Cornell Medical College (WCMC) - Judith Jaffe Multiple Sclerosis Center (JJMSC), New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center/New York Presbyterian, New York
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
RekruttererFase 3
- Weill Cornell Medicine, New York
Behavioral Therapy for Crohn's Disease
Rekrutterer
- Icahn School of Medicine at Mount Sinai, New York
- New York Gastroenterology Associates, New York
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
Rekrutterer
- NYU Langone Health, New York
- Cornell University, New York
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
RekruttererObservasjonsstudie
- New York University, New York
Low Dose IL-2 for the Treatment of Crohn's Disease
RekruttererFase 1/2
- Mount Sinai, New York
Autologous Stem Cell Transplant for Crohn's Disease
RekruttererFase 2
- Icahn School of Medicine at Mount Sinai, New York
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
RekruttererFase 3
- Icahn School of Medicine at Mount Sinai /ID# 262216, New York
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
RekruttererFase 3
- New York Presbyterian Hospital, New York
Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
RekruttererFase 2
- Icahn School of Medicine at Mount Sinai, New York
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
RekruttererFase 3
- Columbia University Medical Center, New York-Presbyterian Hospital, New York
Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
RekruttererFase 4
- Columbia University Medical Center, New York
Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis
Rekrutterer
- Weill Cornell Medical College, New York
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
RekruttererFase 2
- Mirador Therapeutics Selected Site, New York
Pregnant Women With and Without Crohns Disease to Explore the Role of Plastics and Toxins in Intestinal Inflammation
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Icahn School of Medicine at Mount Sinai, New York
Treatment of Moderate to Severe Refractory Crohn's Disease
RekruttererFase 1/2
- Mount Sinai Health Systems, New York
Helmsley 3.0: Abbreviated MRE
RekruttererObservasjonsstudie
- NYU Langone, New York
Crohns sykdom-studier i andre byer
- Boston, MA19 studier
- Miami, FL19 studier
- Cleveland, OH19 studier
- St. Louis, MO19 studier
- Tyler, TX17 studier
- Houston, TX17 studier
- Orlando, FL17 studier
- Atlanta, GA17 studier
- San Antonio, TX15 studier
- San Diego, CA15 studier
- Los Angeles, CA15 studier
- Colorado Springs, CO13 studier
Andre studier i New York City
- Brystkreft136 studier
- Ikke-småcellet lungekreft121 studier
- Kreft (alle typer)109 studier
- Prostatakreft103 studier
- Metastatisk kreft93 studier
- Kolorektal kreft78 studier
- Eggstokkreft69 studier
- Lungekreft60 studier
- Multipelt myelom60 studier
- Pankreaskreft60 studier
- Endometriekreft52 studier
- Akut myelogen leukemi51 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.